Consider
this,
Qiagen is paying €12.90 per share to acquire a 47 percent stake in the company and to purchase all remaining shares afterward. The price represents a 71 percent premium to Ipsogen's share price of €7.53 per share on June 13, the last trading day before the deal was announced.
and
this
Year over year, Ipsogen SA has seen their bottom line shrink from a loss of €2.6M to an even larger loss of €3.4M despite an increase in revenues from €6.7M to €8.4M.
Qiagen are willing to pay a 71% premium for shares of a business that consistently loses money yet we have been advised that the deal to sell Cellestis
represents an attractive price for Cellestis and provides shareholders with an opportunity to realise considerable value from their investment in Cellestis
They must think we are
all stupid.
